Table 4.

Differences in serum potassium between treatment groups throughout the study

Statistical ModelLosartan Versus PlaceboSpironolactone Versus PlaceboSpironolactone Versus Losartan
Unadjusted0.23 (0.04 to 0.42), P=0.020.43 (0.23 to 0.62), P<0.0010.2 (0.0 to 0.39), P=0.05
Adjusted for randomization variablesa0.22 (0.02 to 0.42), P=0.030.37 (0.15 to 0.59), P=0.0010.15 (−0.05 to 0.36), P=0.14
Adjusted for postrandomization variablesa0.25 (0.03 to 0.46), P=0.030.42 (0.21 to 0.64), P<0.0010.17 (−0.03 to 0.46), P=0.16
  • a Variables include systolic BP plasma aldosterone, 24-hour urinary creatinine clearance, 24-hour urinary excretion of sodium and potassium, and 24-hour urine albumin to creatinine ratio. Differences are linear model least squares means estimates and 95% confidence intervals.